title: [Palliative treatment for pain in osseous metastasized prostatic carcinoma with osteotropic rhenium-186 hydroxyethylidene diphosphonate (HEDP)].
abstract: Systemic administration of strontium-89 is an important option for pain relief in advanced prostate carcinoma with multiple osseous metastases. Recently, rhenium-186-HEDP was introduced as a new substance which has important advantages (shorter physical half-life, scintigraphic imaging, dose distribution). The myelosuppressive effect can be estimated more accurately in advance, so that adverse effects can be reduced and the treatment can be repeated after a shorter period of time and more often. Our study comprises 15 treatments with rhenium-186-HEDP in advanced prostate cancer patients using the 1.4- to 2-fold standard dose. The response rate, estimated as reduction in pain and increase in patient mobility, was 87% with no major myelosuppressive effects. The mean duration of pain relief was 4-6 weeks. All four patients with repeated therapy were also responding to the second treatment. Radionuclide therapy for painful osseous metastases with rhenium-186-HEDP appears to be an effective and, even at higher doses, safe procedure.
authors.affiliation: Abteilung für Nuklearmedizin der Radiologischen Klinik, Universitätskliniken des Saarlandes, Homburg/Saar.
authors.forename: L H
authors.initials: LH
authors.lastname: Holle
authors.forename: U
authors.initials: U
authors.lastname: Humke
authors.forename: L
authors.initials: L
authors.lastname: Trampert
authors.forename: M
authors.initials: M
authors.lastname: Ziegler
authors.forename: C M
authors.initials: CM
authors.lastname: Kirsch
authors.forename: E
authors.initials: E
authors.lastname: Oberhausen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000532:radiotherapy* / Q000556:secondary*; D004164:Diphosphonates; D012968:Etidronic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; D010146:Pain / Q000209:etiology / Q000532:radiotherapy*; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology / Q000532:radiotherapy*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D011878:Radiotherapy / Q000009:adverse effects; D012211:Rhenium / Q000627:therapeutic use
chemical_list: D004164:Diphosphonates; D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C033905:technetium Tc 99m 1,1-diphosphonopropane-2,3-dicarboxylic acid; C101598:rhenium-186 HEDP; D012211:Rhenium; D012968:Etidronic Acid
vernacular_title: Palliative Schmerztherapie beim ossär metastasierten Prostatakarzinom mit dem osteotropen beta-Strahler 186Rhenium-Hydroxyethylidendiphosphonat (HEDP).